Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
pharmaphorum
JANUARY 6, 2021
Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. In 2019 the Danish company also licensed a preclinical-stage, small-molecule candidate for NASH from Japan’s UBE.
65 
Let's personalize your content